The DOI matches its Crossref record.
Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD
Open accessAbstract
BACKGROUND: New medical therapies have improved outlook in inflammatory bowel disease but published impact on surgical rates has been modest suggesting that many patients are still not attaining remission. AIM: To review remission rates with current medical treatments for inflammatory bowel disease. METHODS: We searched MEDLINE (source PUBMED, 1966 to January, 2011). RESULTS: Induction and maintenance of remission was observed in 20% (range, 9-29.5%) and 53% (range, 36.8-59.6%) of ulcerative colitis (UC) patients treated with oral 5-ASA derivatives. Induction of remission was noted in 52% (range, 48-58%) of Crohn's disease (CD) patients and 54% of UC patients treated with steroids in population-based cohorts. Maintenance of remission was reported in 71% (range, 56-95%) of CD patients on azathioprine over a 6-month to 2-year period and in 60% (range, 41.7-82.4%) in UC at 1 year or longer. Induction and maintenance of remission was noted in 39% (range, 19.3-66.7%) and 70% (range, 39-90%) of CD patients on methotrexate over a 40-week period. Induction of remission was reported in 32% (range, 25-48%), 26% (range, 18-36%) and 20% (range, 19-23%) of CD patients on infliximab, adalimumab or certolizumab pegol, respectively. The corresponding figures were 45% (range, 39-59%), 43% (range, 40-47%) and 47.9% at weeks 20-30 among initial responders. Induction of remission was observed in 33% (range, 27.5-38.8%) and 18.5% of UC patients on infliximab or adalimumab, respectively. Maintenance of remission was noted in 33% (range, 25.6-36.9%) of UC patients on infliximab at week 30. Approximately one-fifth of CD and UC patients treated with biologicals require intestinal resection after 2-5 years in referral-centre studies. CONCLUSION: In the era of biologics, the proportion of patients with inflammatory bowel disease not entering remission remains high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Self-citationBonaz, B., Sinniger, V., & Pellissier, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01452 · Cited by 405
New therapies for inflammatory bowel disease: from the bench to the bedside
Danese, S. (2012) · Gut · doi:10.1136/gutjnl-2011-300904 · Cited by 308
Bessissow, T., Lemmens, B., Ferrante, M., Bisschops, R., Van Steen, K., Geboes, K., Van Assche, G., Vermeire, S., Rutgeerts, P., & De Hertogh, G. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.301 · Cited by 292
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Wyant, T., Fedyk, E., & Abhyankar, B. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw092 · Cited by 284
Metadata
- Authors
- Peyrin-Biroulet, L., & Lémann, M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-02-15
- Volume
- 33
- Issue
- 8
- Pages
- 870-879
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W1857468674
- Cited by
- 196
- References
- 0
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. https://app.cochat.ai/papers/10.1111/j.1365-2036.2011.04599.x
- The paper
- Peyrin-Biroulet, L., & Lémann, M. (2011). Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2011.04599.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.